New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For NYX;ICE;MDRX;VVUS;ELOQ;ORCL;RAD;JBL;CAG;BBBY;DFS;FOLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
March 19, 2015
10:42 EDTFOLD, ORCLOptions with decreasing implied volatility
Subscribe for More Information
10:23 EDTFOLDHigh option volume stocks
Subscribe for More Information
09:37 EDTRAD, FOLDActive equity options trading on open
Subscribe for More Information
09:20 EDTFOLDOn The Fly: Pre-market Movers
Subscribe for More Information
08:34 EDTMDRXAllscripts and NoteSwift enter into collaboration agreement
NoteSwift and Allscripts have entered into an agreement for Allscripts to market and resell NoteSwift 2.0 for Allscripts Professional EHR. In response to customer demand, this strategic agreement may help providers reduce the time spent on creating patient documentation by more than half through the use of medical speech recognition.
08:20 EDTFOLDAmicus to host conference call
Subscribe for More Information
07:59 EDTFOLDAmicus NDA submission removes key overhang, says JPMorgan
Subscribe for More Information
07:04 EDTRADAmerican Express confirms plans to launch Plenti loyalty program
Subscribe for More Information
06:15 EDTMDRXAllscripts coverage transferred with an Outperform at RW Baird
Subscribe for More Information
06:07 EDTFOLDAmicus reports positive results in meetings with EMA and FDA
Amicus has met with regulatory authorities in Europe and the U.S. to discuss the approval pathways for the oral small molecule pharmacological chaperone migalastat HCl as a precision medicine monotherapy for Fabry patients who have amenable genetic mutations. The company held a meeting with the assigned European Rapporteurs to discuss the upcoming marketing authorization application for migalastat monotherapy. The Rapporteurs agreed that Amicus may submit its MAA for migalastat monotherapy under the Full Approval pathway in the EU and indicated support for Amicus to request Accelerated Assessment. Amicus is accelerating the timing of the MAA submission for full approval for migalastat monotherapy from the middle of 2015 to Q2. Amicus held a Type C meeting with the FDA and plans to submit an NDA for Accelerated Approval, for which the FDA is open to considering several potential surrogate endpoints evaluated in the clinical studies of migalastat. Amicus plans to schedule a pre-NDA meeting and to submit an NDA under Subpart H in 2H15
05:49 EDTRADStocks with implied volatility movement; RAD XLV
Subscribe for More Information
March 18, 2015
18:32 EDTJBLOn The Fly: After Hours Movers
UP AFTER EARNINGS: Guess (GES), up 12.4% after reporting fourth quarter results and guidance... Shoe Carnival (SCVL), up 10%... NQ Mobile (NQ), up 9.1%... Tilly's (TLYS), up 1.3%... Cintas (CTAS), up 1.3% after reporting quarterly results and raising fiscal 2015 guidance. DOWN AFTER EARNINGS: Williams-Sonoma (WSM), down 4.1%... Jabil Circuit (JBL), down 1.8%... Juno Therapeutics (JUNO), down 3.3%. ALSO LOWER: Concert Pharmaceuticals (CNCE), down 4.4% after filing to sell common stock... Tekmira Pharmaceuticals (TKMR), down 3.7% after filing to sell 6M shares of common stock.
16:26 EDTORCLOn The Fly: Closing Wrap
Subscribe for More Information
16:12 EDTJBLJabil Circuit backs FY15 core EPS view of $1.85-$2.15, consensus $2.03
Subscribe for More Information
16:10 EDTJBLJabil Circuit sees Q3 core EPS 43c-55c, consensus 47c
Subscribe for More Information
16:09 EDTJBLJabil Circuit reports Q2 core EPS 50c, consensus 45c
Subscribe for More Information
16:00 EDTRADOptions Update; March 18, 2015
iPath S&P 500 VIX Short-Term Futures down 1.20 to 26.10. Option volume leaders: AAPL RAD PBR TWTR FB TSLA CLF BP MGM according to Track Data.
15:20 EDTJBLNotable companies reporting after market close
Subscribe for More Information
12:38 EDTORCLOn The Fly: Midday Wrap
Stocks on Wall Street were lower at midday ahead of the conclusion of the Federal Reserve's latest rate setting meeting and the central bank's accompanying announcements. The averages began the session in negative territory and have been range-bound throughout the morning. The Dow was down triple digits once again, making 8 consecutive days that the blue chip index has seen a triple digit move. ECONOMIC EVENTS: In the U.S., the DOE petroleum inventory reports showed a 9.6M barrel rise in crude stocks in the week of March 13, versus expectations for a 4.4M build. The day's big economic news is yet to come, with the Fed's FOMC meeting announcement due at 2:00 pm EDT and Fed Chair Yellen holding a press conference a half hour later. Elsewhere, Prime Minister Benjamin Netanyahu unexpectedly defeated his main challenger in Israelís election and his Likud party appears set to capture more parliament seats. COMPANY NEWS: Shares of FedEx (FDX) slid 2.5% after the shipping giant reported earnings that beat estimates, but revenue that fell short of the consensus forecast, for its third fiscal quarter. FedEx noted that it expects to deliver "record" yearly earnings for the current fiscal year and next fiscal year as well... Oracle (ORCL) shares rose 2.5% after the company's third quarter profits matched expectations and it raised its quarterly dividend 25%. MAJOR MOVERS: Among the notable gainers was Vitesse Semiconductor (VTSS), which jumped 37% after the company agreed to be acquired for $5.28 per share in cash by Microsemi (MSCC). Also higher was Retrophin (RTRX), which rose 28% after the company said it will exercise its right to purchase from Asklepion Pharmaceuticals all worldwide rights, titles, and ownership of Cholbam after the FDA approved the drug for the treatment of pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for patients with peroxisomal disorders. Among the noteworthy losers was Willbros Group (WG), which dropped 55% and was downgraded to Underperform at DA Davidson after announcing its earnings report will be delayed and the company is in potential non-compliance with debt covenants. Also lower following their earnings reports were Nektar Therapeutics (NKTR), which fell 15% after the company's Phase III BEACON metastatic breast cancer study missed its primary endpoint. INDEXES: Near midday, the Dow was down 105.02, or 0.59%, to 17,744.06, the Nasdaq was down 12.45, or 0.25%, to 4,924.99, and the S&P 500 was down 7.69, or 0.37%, to 2,066.59.
10:30 EDTRADRite Aid calls active on renewed takeover speculation
Rite Aid April 8 and 9 calls are active on 138K contracts (1K puts) on renewed takeover speculation. March call option implied volatility is at 72, April is at 62, May is at 53; compared to its 26-week average of 44 according to Track Data. Active call volume suggests traders taking positions for larger near term price movement.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use